Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
male (14) 14
animals (11) 11
endocrinology & metabolism (10) 10
humans (10) 10
type 2 diabetes (10) 10
diabetes (8) 8
rats (8) 8
aged (7) 7
diabetes mellitus, type 2 - drug therapy (7) 7
female (7) 7
glucagon-like peptides - analogs & derivatives (7) 7
middle aged (7) 7
rats, sprague-dawley (7) 7
exenatide (6) 6
kidney diseases (6) 6
kidneys (6) 6
liraglutide (6) 6
risk factors (6) 6
treatment outcome (6) 6
diabetes mellitus (5) 5
drug administration schedule (5) 5
dulaglutide (5) 5
expression (5) 5
glucagon-like peptide-1 (5) 5
glucagon-like peptide-1 receptor - agonists (5) 5
hypertension (5) 5
insulin (5) 5
insulin glargine (5) 5
oxidative stress (5) 5
peripheral vascular disease (5) 5
rodents (5) 5
blood pressure (4) 4
blood pressure - physiology (4) 4
chronic kidney failure (4) 4
diabetes mellitus, type 2 - blood (4) 4
efficacy (4) 4
epidermal growth factor receptors (4) 4
glomerular filtration rate (4) 4
glucagon-like peptides - administration & dosage (4) 4
glucagon-like peptides - therapeutic use (4) 4
glycosylated hemoglobin (4) 4
heme oxygenase (4) 4
heme oxygenase - metabolism (4) 4
hypoglycemic agents - therapeutic use (4) 4
immunoglobulin fc fragments - administration & dosage (4) 4
immunoglobulin fc fragments - therapeutic use (4) 4
kidney - metabolism (4) 4
once-weekly dulaglutide (4) 4
physiology (4) 4
recombinant fusion proteins - administration & dosage (4) 4
recombinant fusion proteins - therapeutic use (4) 4
renal impairment (4) 4
research (4) 4
therapy (4) 4
urology & nephrology (4) 4
abridged index medicus (3) 3
adult (3) 3
ang ii-dependent hypertension (3) 3
biomarkers - blood (3) 3
blood glucose - drug effects (3) 3
blood glucose - metabolism (3) 3
carbon monoxide (3) 3
cardiac & cardiovascular systems (3) 3
clinical trials, phase iii as topic (3) 3
creatinine (3) 3
diabetes mellitus, type 2 - complications (3) 3
diabetes mellitus, type 2 - metabolism (3) 3
diabetes therapy (3) 3
drug therapy (3) 3
enzyme inhibitors - pharmacology (3) 3
estimated glomerular filtration rate (3) 3
exendin-4 (3) 3
glp-1 (3) 3
glucagon (3) 3
glucagon-like peptide-1 receptor - metabolism (3) 3
glucagon-like peptides - adverse effects (3) 3
glycemic control (3) 3
hemoglobin (3) 3
hypoglycemic agents - administration & dosage (3) 3
immunoglobulin fc fragments - adverse effects (3) 3
immunohistochemistry (3) 3
incretin (3) 3
kidney (3) 3
medicine, general & internal (3) 3
patients (3) 3
peptides (3) 3
prospective studies (3) 3
recombinant fusion proteins - adverse effects (3) 3
safety (3) 3
2k1c (2) 2
adolescent (2) 2
alternative transcriptional start (2) 2
ang-ii (2) 2
angiotensin i - metabolism (2) 2
angiotensin ii (2) 2
angiotensin ii - pharmacology (2) 2
angiotensin-ii (2) 2
apoptosis (2) 2
arhgef18 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events
by Ferdinand, Keith C and Botros, Fady T and Atisso, Charles M and Sager, Philip T
Cardiovascular Diabetology, ISSN 1475-2840, 02/2016, Volume 15, Issue 1, pp. 38 - 38
Background: Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without... 
Glucagon-like peptide-1 (GLP-1) | Type 2 diabetes | Cardiovascular events | Incretin | MACE | Meta-analysis | METFORMIN | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | INTENSIVE GLUCOSE CONTROL | EXENATIDE | FOLLOW-UP | MELLITUS | PEPTIDE-1 ANALOG | RECEPTOR AGONIST DULAGLUTIDE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 233-OR: Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) vs. Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7
by TUTTLE, KATHERINE R and RAYNER, BRIAN L and LAKSHMANAN, MARK and WOODWARD, BRAD and KWAN, ANITA and KONIG, MANIGE and BOTROS, FADY T
Diabetes, ISSN 0012-1797, 06/2019, Volume 68, Issue Supplement 1, p. 233
In the AWARD-7 study, conducted in T2D and moderate-to-severe CKD, DU treatment was associated with slower decline in estimated glomerular filtration rate... 
End-stage renal disease | Epidermal growth factor receptors | Diabetes mellitus | Population studies | Blood pressure | Kidney diseases | Diabetes | Diabetes mellitus (non-insulin dependent) | Insulin | Glomerular filtration rate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip goldblatt hpertensive rats
by Prieto-Carrasquero, Minolfa C and Botros, Fady T and Pagan, Javier and Kobori, Hiroyuki and Seth, Dale M and Casarini, Dulce E and Navar, L. Gabriel
Hypertension, ISSN 0194-911X, 06/2008, Volume 51, Issue 6, pp. 1590 - 1596
Prorenin | Renin western blot | Renin mRNA | Ang II-dependent hypertension | Angiotensin II | Tubular renin | Renin immunostaining
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
by Tuttle, Katherine R and McKinney, T. Dwight and Davidson, Jaime A and Anglin, Greg and Harper, Kristine D and Botros, Fady T
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2017, Volume 19, Issue 3, pp. 436 - 441
Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and... 
clinical trial | GLP | type 2 diabetes | diabetes complications | dulaglutide | diabetic nephropathy | GLP-1 | EXENATIDE | RENAL IMPAIRMENT | NEPHROPATHY | NATRIURESIS | GLUCAGON-LIKE PEPTIDE-1 | LIRAGLUTIDE | EXENDIN-4 | DISEASE | ENDOCRINOLOGY & METABOLISM | RECEPTOR AGONIST | PROGRESSION | Hypoglycemic Agents - therapeutic use | Glomerular Filtration Rate | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Insulin Glargine - therapeutic use | Male | Treatment Outcome | Albuminuria | Diabetes Mellitus, Type 2 - metabolism | Creatinine - urine | Kidney Function Tests | Clinical Trials, Phase III as Topic | Female | Acute Kidney Injury - chemically induced | Aged | Glucagon-Like Peptides - therapeutic use | Immunoglobulin Fc Fragments - therapeutic use | Acute Kidney Injury - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptides - analogs & derivatives | Glucagon-Like Peptide-1 Receptor - agonists | Clinical Trials, Phase II as Topic | Type 2 diabetes | Complications and side effects | Chronic kidney failure | Glucagon | Diabetic nephropathies | Clinical trials | Albumin | Epidemiology | Insulin | Diabetes | Index Medicus | Brief Reports | Brief Report | GLP‐1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
: Review of Dulaglutide Clinical Trial Program
by Jendle, Johan and Grunberger, George and Blevins, Thomas and Giorgino, Francesco and Hietpas, Ryan T and Botros, Fady T
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 11/2016, Volume 32, Issue 8, pp. 776 - 790
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study
by Oudiz, Ronald J and Brundage, Bruce H and Gali, Nazzareno and Ghofrani, Hossein Ardeschir and Simonneau, Gerald and Botros, Fady T and Chan, Melanie and Beardsworth, Anthony and Barst, Robyn J and PHIRST Study Grp and PHIRST Study Group
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2012, Volume 60, Issue 8, pp. 768 - 774
The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary arterial hypertension. Tadalafil is an oral... 
pulmonary arterial hypertension | PDE-5 | tadalafil | SURVIVAL | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | 1ST-LINE BOSENTAN | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Phosphodiesterase 5 Inhibitors - administration & dosage | Antihypertensive Agents - administration & dosage | Familial Primary Pulmonary Hypertension | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Carbolines - administration & dosage | Tadalafil | Analysis of Variance | Sulfonamides - therapeutic use | Adult | Female | Aged | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Carbolines - therapeutic use | Vasodilator Agents - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Baseline factors associated with glycaemic response to treatment with once‐weekly dulaglutide in patients with type 2 diabetes
by Wysham, Carol and Guerci, Bruno and D'Alessio, David and Jia, Nan and Botros, Fady T
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2016, Volume 18, Issue 11, pp. 1138 - 1142
Dulaglutide glycaemic efficacy has been demonstrated in the AWARD clinical trial programme. The objective of the present analysis was to determine the major... 
type 2 diabetes | dulaglutide | EFFICACY | SAFETY | SITAGLIPTIN | EXENATIDE | OPEN-LABEL | PHASE-3 | NON-INFERIORITY | METFORMIN-TREATED PATIENTS | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | INSULIN GLARGINE | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Metformin - adverse effects | Young Adult | Fasting - blood | Adult | Female | Hypoglycemia - blood | Metformin - administration & dosage | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Glycosylated hemoglobin | Care and treatment | Diabetes therapy | Rodents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
by Tuttle, Katherine R and Lakshmanan, Mark C and Rayner, Brian and Zimmermann, Alan G and Woodward, Brad and Botros, Fady T
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2019, Volume 21, Issue 6, pp. 1493 - 1497
In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline... 
GLP‐1 | type 2 diabetes | GLP-1 | ENDOCRINOLOGY & METABOLISM | Type 2 diabetes | Insulin glargine | Chronic kidney failure | Body weight | Diabetes therapy | Creatinine | Cystatin | Kidneys | Epidermal growth factor receptors | Cattle | Diabetes mellitus | Cystatin C | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Insulin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting
by Boye, K and Mody, R and Wu, JM and Lage, MJ and Botros, FT and Woodward, B
DIABETES, ISSN 0012-1797, 07/2018, Volume 67, Issue Supplement 1, p. 1557
ENDOCRINOLOGY & METABOLISM
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text GLP-1 receptor agonists, CKD, and eGFR trajectory – Authors' reply
by Tuttle, Katherine R and Lakshmanan, Mark C and Rayner, Brian and Busch, Robert S and Zimmermann, Alan G and Woodward, D Bradley and Botros, Fady T
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 10/2018, Volume 6, Issue 10, pp. 765 - 765
Hypoglycemic Agents | Renal Insufficiency, Chronic | Glomerular Filtration Rate | Humans | Glucagon-Like Peptide-1 Receptor - agonists | ErbB Receptors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting
by Boye, Kristina S and Mody, Reema and Wu, Jianmin and Lage, Maureen J and Botros, Fady T and Woodward, Brad
Clinical Therapeutics, ISSN 0149-2918, 08/2018, Volume 40, Issue 8, pp. 1396 - 1407
The aims of this study were to use real-world treatment results to compare changes in estimated glomerular filtration rate (eGFR) and glycosylated hemoglobin... 
dulaglutide | glycosylated hemoglobin | estimated glomerular filtration rate | insulin glargine | EFFICACY | EXENATIDE | RENAL IMPAIRMENT | DIABETES-MELLITUS | LIRAGLUTIDE | ICD-9-CM | KIDNEY-FUNCTION | ONCE-WEEKLY DULAGLUTIDE | PHARMACOLOGY & PHARMACY | OUTCOMES | TYPE-2 | Type 2 diabetes | Glycosylated hemoglobin | Medical records | Insulin | Analysis | Creatinine | Therapy | Statistical analysis | Calipers | Renal function | Filtration | Epidermal growth factor receptors | Laboratories | Diabetes mellitus | Impairment | Hypoglycemia | Patients | Electronic medical records | Glomerular filtration rate | Laboratory tests | Reduction | Hemoglobin | Adults | Diabetes | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Electronic health records
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
by Ferdinand, Keith C and Botros, Fady T and Atisso, Charles M and Sager, Philip T
Cardiovascular diabetology, 02/2016, Volume 15, p. 38
Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without diabetes.... 
Prospective Studies | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Protective Factors | Clinical Trials, Phase III as Topic | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - mortality | Female | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - etiology | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - mortality | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
by Tuttle, Katherine R and Lakshmanan, Mark C and Rayner, Brian and Busch, Robert S and Zimmermann, Alan G and Woodward, D Bradley and Botros, Fady T
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 08/2018, Volume 6, Issue 8, pp. 605 - 617
Many antihyperglycaemic drugs, including insulin, are primarily cleared by the kidneys, restricting treatment options for patients with kidney disease.... 
PEPTIDE-1 RECEPTOR AGONIST | GLP-1 | LIRAGLUTIDE | EXENDIN-4 | EXENATIDE | ENDOCRINOLOGY & METABOLISM | ONCE-WEEKLY DULAGLUTIDE | OUTCOMES | RENAL IMPAIRMENT | NEPHROPATHY | PROGRESSION | Glycated Hemoglobin A - analysis | Prognosis | Follow-Up Studies | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - drug therapy | Hypoglycemia - prevention & control | Renal Insufficiency, Chronic - metabolism | Young Adult | Adult | Female | Immunoglobulin Fc Fragments - therapeutic use | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Hyperglycemia - prevention & control | Blood Glucose - analysis | Biomarkers - analysis | Insulin Glargine - therapeutic use | Renal Insufficiency, Chronic - pathology | Adolescent | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - pathology | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Complications and side effects | Insulin glargine | Chronic kidney failure | Dosage and administration | Research | Drug therapy | Comparative analysis | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes
by Lage, Maureen J and Boye, Kristina S and Bae, Jay Patrick and Wu, Jianmin and Mody, Reema and Botros, Fady T
Journal of medical economics, 02/2019, p. 1
Examine healthcare costs across chronic kidney disease (CKD) stages for US patients with type 2 diabetes (T2D). IQVIA Real World Data Adjudicated Claims linked... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Expression of novel “LOCGEF” isoforms of ARHGEF18 in eosinophils
by Turton, Keren B and Wilkerson, Emily M and Hebert, Alex S and Fogerty, Frances J and Schira, Hazel M and Botros, Fady E and Coon, Joshua J and Mosher, Deane F
Journal of Leukocyte Biology, ISSN 0741-5400, 07/2018, Volume 104, Issue 1, pp. 135 - 145
Genomic, transcriptomic and proteomic databases indicate that the N‐terminal 322 residues encoded by the presumptive LOC100996504 gene, which is adjacent to... 
granulocyte | alternative transcriptional start | ARHGEF18 | LOC100996504 | guanine nucleotide exchange factor | p114‐GEF | p114-GEF | guanine nucleotide exchange factor (GEF)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Lesser eGFR Decline with Dulaglutide Regardless of Weight Changes in People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease (AWARD-7)
by Tuttle, KR and Lakshmanan, M and Rayner, BL and Busch, RS and Zimmermann, AG and Woodward, B and Botros, FT
DIABETES, ISSN 0012-1797, 07/2018, Volume 67, Issue Supplement 1, p. 1066
ENDOCRINOLOGY & METABOLISM
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles
by Botros, Fady T and Navar, LGabriel
American Journal of Physiology: Cell Physiology, ISSN 0363-6143, 12/2006, Volume 291, Issue 6, pp. H2772 - H2778
Heme oxygenases (HO-1 and HO-2) catalyze the conversion of heme to carbon monoxide (CO), iron, and biliverdin. CO causes vasorelaxation via stimulation of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Expression of novel "LOCGEF" isoforms of ARHGEF18 in eosinophils
by Turton, KB and Wilkerson, EM and Hebert, AS and Fogerty, FJ and Schira, HM and Botros, FE and Coon, JJ and Mosher, DF
JOURNAL OF LEUKOCYTE BIOLOGY, ISSN 0741-5400, 07/2018, Volume 104, Issue 1, pp. 135 - 145
Genomic, transcriptomic and proteomic databases indicate that the N-terminal 322 residues encoded by the presumptive LOC100996504 gene, which is adjacent to... 
HUMAN PROTEOME | P114RHOGEF | ACTIVATION | ARHGEF18 | IMMUNOLOGY | IDENTIFICATION | CELL BIOLOGY | granulocyte | MORPHOGENESIS | LOC100996504 | guanine nucleotide exchange factor | RNA-SEQ | JUNCTIONS | alternative transcriptional start | NUCLEOTIDE EXCHANGE FACTOR | RHO GTPASES | p114-GEF | HEMATOLOGY | BINDING | Cell Polarity - physiology | Eosinophils - metabolism | Rho Guanine Nucleotide Exchange Factors - biosynthesis | Protein Isoforms - metabolism | Humans | Proteomics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
by Mathieu, Chantal and Del Prato, Stefano and Botros, Fady T and Thieu, Vivian T and Pavo, Imre and Jia, Nan and Haupt, Axel and Karanikas, Chrisanthi A and García‐Pérez, Luis‐Emilio
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2023 - 2028
Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion.... 
beta‐cell function | GLP | type 2 diabetes | dulaglutide | 1 receptor agonist | beta-cell function | GLP-1 receptor agonist | METFORMIN | EFFICACY | SAFETY | EXENATIDE | INSULIN | GLUCAGON-LIKE PEPTIDE-1 | LIRAGLUTIDE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | ONCE-WEEKLY DULAGLUTIDE | DYSFUNCTION | Glycated Hemoglobin A - analysis | C-Peptide - blood | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Glucagon-Like Peptide-1 Receptor - metabolism | Insulin-Secreting Cells - metabolism | Hypoglycemic Agents - administration & dosage | Female | Immunoglobulin Fc Fragments - therapeutic use | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Recombinant Fusion Proteins - administration & dosage | Insulin Secretion - drug effects | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Insulin Resistance | Biomarkers - blood | Disease Progression | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Type 2 diabetes | Medical research | Pancreatic beta cells | Peptides | Blood sugar | Glycosylated hemoglobin | Medicine, Experimental | Fasting | Glucagon | Secretion | Diabetes mellitus | Glucose | Insulin | Patients | Blood | Beta cells | Lymphocytes B | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Index Medicus | GLP‐1 receptor agonist | Brief Report | Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights